Key Highlights

  • The second quarter brought a USD 14.4 million net loss, equivalent to 0.66 per share, the same per-share figure recorded a year earlier.
  • USD 73.9 million was held in cash, cash equivalents and short-term investments at June 30, 2026, a fall from USD 91.2 million at March 31, 2026, and management expects that to last into late 2027.
  • Research and development expense dropped to USD 10.5 million from USD 13.1 million a year earlier, following the trial pause and the FDA clinical hold imposed in May 2026.
  • G&A costs rose to USD 4.6 million, compared with USD 2.7 million, and that total contained USD 0.5 million of severance linked to a June 2026 cut in headcount.

Comparisons to Prior Periods Ahead of the Aardvark Therapeutics (NASDAQ:AARD) Release

Aardvark Therapeutics (NASDAQ:AARD) has third quarter 2026 results scheduled for November 16, 2026, with the second quarter serving as the benchmark. In that quarter the loss came to USD 14.4 million, which works out to 0.66 per share, flat on the year. Spending on operations came to USD 15.1 million against USD 15.8 million, and other income (net) dropped to USD 0.7 million from USD 1.5 million. Over the first half, the loss amounted to USD 36.0 million, equal to 1.65 per share, compared with USD 23.7 million, or 1.36 per share, a year ago. The company is at a clinical stage and generates no product sales.

FDA Hold and Trial Termination Shaping the Quarter for Aardvark Therapeutics (NASDAQ:AARD)

The quarter was dominated by actions around ARD-101, the lead candidate for Prader-Willi syndrome. In May 2026 the FDA imposed a full clinical hold on the ARD-101 IND, which followed a voluntary pause. The company ended the HERO Phase 3 study and its open-label extension in June 2026, stating it does not presently plan to resume them as originally designed. Management is reviewing unblinded HERO and extension data during the third quarter of 2026 to decide next steps, and it remains in active talks with the FDA about the hold. A workforce cut came in June 2026, and no readout date for HERO was given.

Cash Decline, Runway and Equity Base at Aardvark Therapeutics (NASDAQ:AARD)

Aardvark Therapeutics (NASDAQ:AARD) closed June 2026 with USD 73.9 million in cash and short-term investments, after a calculated USD 17.3 million reduction from the March 31, 2026 figure. Management believes this balance funds planned activity through late 2027. The Balance Sheet shows USD 81.5 million of assets, USD 6.7 million of liabilities and USD 74.8 million of equity. As of June 30, 2026, 21,884,158 shares were outstanding, against 21,815,353 at year-end 2025. Key risks include the regulatory route for ARD-101, the findings of the data review, further cost cuts and funding needs beyond the guided runway.

Where Things Stand

Aardvark Therapeutics (NASDAQ:AARD) approaches its November 16, 2026 release after a difficult stretch: an FDA clinical hold in May 2026, the June 2026 end of the HERO and extension studies, and a staff cut. The quarter's USD 14.4 million loss, at 0.66 per share, was unchanged on a per-share basis. Research expense slid to USD 10.5 million, whereas admin spending increased to USD 4.6 million. Holding USD 73.9 million of cash and investments with runway guided into late 2027, the most important item will be the update on unblinded data and talks with regulators.